IONS|Ionis Pharmaceuticals Inc|Preço:75.710|Var. %:-0.31

Mais detalhes de Ionis Pharmaceuticals Inc Empresa

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Informações de Ionis Pharmaceuticals Inc



Código da empresaIONS

Nome da EmpresaIonis Pharmaceuticals Inc

Data de listagemMay 17, 1991

CEOMonia (Brett P)

Número de funcionários1069

Tipo de títulosOrdinary Share

Fim do ano fiscalMay 17

Endereço2855 Gazelle Court

CidadeCARLSBAD

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal92010

Telefone17609319200

Sitehttps://www.ionis.com/

Código da empresaIONS

Data de listagemMay 17, 1991

CEOMonia (Brett P)

Executivos da empresa Ionis Pharmaceuticals Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

242.66K

-5.08%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

--

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

82.66K

-60.76%

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

67.50K

+1.34%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

62.21K

-16.31%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

59.86K

-9.71%

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

59.66K

--

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Chairman of the Board

36.33K

--

Dr. Eric E. Swayze, Ph.D.

Executive Vice President - Research

32.68K

+0.61%

Mr. Kyle Jenne

Executive Vice President, Chief Global Product Strategy Officer

23.71K

+30.89%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

242.66K

-5.08%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

--

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

82.66K

-60.76%

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

67.50K

+1.34%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

62.21K

-16.31%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

59.86K

-9.71%

Detalhamento da receita

Moeda: USDAtualizado em: 4 de mar de 2025

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

Os dados relevantes ainda não foram divulgados pela empresa.

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

Distribuição de ações

Atualizado em: há 16 horas

Investidores

Tipos de investidores

Investidores

Proporção

Fidelity Management & Research Company LLC

14.57%

Capital World Investors

10.87%

T. Rowe Price Investment Management, Inc.

5.51%

BlackRock Institutional Trust Company, N.A.

5.22%

Vanguard Portfolio Management, LLC

4.73%

Outro

59.10%

Investidores

Proporção

Fidelity Management & Research Company LLC

14.57%

Capital World Investors

10.87%

T. Rowe Price Investment Management, Inc.

5.51%

BlackRock Institutional Trust Company, N.A.

5.22%

Vanguard Portfolio Management, LLC

4.73%

Outro

59.10%

Tipos de investidores

Investidores

Proporção

Investment Advisor

82.89%

Investment Advisor/Hedge Fund

19.99%

Hedge Fund

12.11%

Research Firm

1.99%

Pension Fund

1.17%

Bank and Trust

0.87%

Individual Investor

0.72%

Sovereign Wealth Fund

0.19%

Insurance Company

0.16%

Participação acionária institucional



Atualizado em: qua, 1 de abr

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2026Q1

942

197.51M

119.51%

+12.09M

2025Q4

884

176.89M

109.21%

-8.44M

2025Q3

815

172.95M

106.78%

-7.24M

2025Q2

801

185.40M

116.34%

+8.33M

2025Q1

826

174.18M

109.45%

-1.97M

2024Q4

819

166.51M

104.84%

-2.69M

2024Q3

814

162.85M

103.55%

+6.60M

2024Q2

810

149.96M

102.64%

-3.87M

2024Q1

792

148.14M

101.63%

-5.27M

2023Q4

782

147.15M

102.53%

-3.26M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Fidelity Management & Research Company LLC

24.07M

14.57%

+383.06K

+1.62%

Dec 31, 2025

Capital World Investors

17.96M

10.87%

+5.24M

+41.17%

Dec 31, 2025

T. Rowe Price Investment Management, Inc.

9.11M

5.51%

-4.05M

-30.77%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

8.63M

5.23%

+180.41K

+2.13%

Dec 31, 2025

Wellington Management Company, LLP

6.26M

3.79%

-328.49K

-4.99%

Dec 31, 2025

Two Sigma Investments, LP

5.72M

3.46%

+2.07M

+56.76%

Dec 31, 2025

Bellevue Asset Management AG

4.80M

2.91%

-1.44M

-23.10%

Dec 31, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sáb, 6 de dez

Nome

Proporção

Invesco Biotechnology & Genome ETF

5.24%

ARK Genomic Revolution ETF

4.11%

Virtus LifeSci Biotech Products ETF

3.34%

Franklin Genomic Advancements ETF

2.69%

Invesco Dorsey Wright Healthcare Momentum ETF

2.57%

First Trust Health Care Alphadex Fund

2.47%

VanEck Morningstar SMID Moat ETF

2.38%

WisdomTree BioRevolution Fund

2.28%

State Street SPDR S&P Biotech ETF

2.28%

Capital Group US Small and Mid Cap ETF

2.04%

Ver Mais

Invesco Biotechnology & Genome ETF

Proporção5.24%

ARK Genomic Revolution ETF

Proporção4.11%

Virtus LifeSci Biotech Products ETF

Proporção3.34%

Franklin Genomic Advancements ETF

Proporção2.69%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporção2.57%

First Trust Health Care Alphadex Fund

Proporção2.47%

VanEck Morningstar SMID Moat ETF

Proporção2.38%

WisdomTree BioRevolution Fund

Proporção2.28%

State Street SPDR S&P Biotech ETF

Proporção2.28%

Capital Group US Small and Mid Cap ETF

Proporção2.04%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados